trial · primary record
Enasidenib
Metastatic Chondrosarcoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2030-12-31 |
| Primary endpoint | Progression Free Survival (PFS) in all study participants |
| Registry ID | NCT06176989 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:41.921Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06176989
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.